Litigation Details for Anacor Pharmaceuticals, Inc. v. Teva Pharmaceuticals Development, Inc. (D. Del. 2021)
✉ Email this page to a colleague
Anacor Pharmaceuticals, Inc. v. Teva Pharmaceuticals Development, Inc. (D. Del. 2021)
| Docket | ⤷ Sign Up | Date Filed | 2021-09-24 |
| Court | District Court, D. Delaware | Date Terminated | 2023-06-15 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | |
| Parties | PF PRISM IMB B.V. | ||
| Patents | 8,168,614; 8,501,712; 9,682,092 | ||
| Attorneys | Nathan Roger Hoeschen | ||
| Firms | Morris, Nichols, Arsht & Tunnell | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Anacor Pharmaceuticals, Inc. v. Teva Pharmaceuticals Development, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Anacor Pharmaceuticals, Inc. v. Teva Pharmaceuticals Development, Inc. (D. Del. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2021-09-24 | 1 | Complaint | of U.S. Patent No. 8,168,614 (“the ’614 patent”), U.S. Patent No. 8,501,712 (“the ’712 patent”), and …and U.S. Patent No. 9,682,092 (“the ’092 patent”). The ’614 patent, the ’712 patent, and the ’092 patent… This is a civil action for patent infringement under the patent laws of the United States, Title… THE PATENTS-IN-SUIT 11. On May 1, 2012, the United States Patent and Trademark …the ’614 patent. 13. PF PRISM IMB B.V. is the exclusive licensee of the ’614 patent. | External link to document |
| 2021-09-24 | 4 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,168,614 B2 ;8,501,712 B2 ;9,682,092…2021 15 June 2023 1:21-cv-01353 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
